SCHEMBL31161062

SCHEMBL31161062

COc1cccc2[nH]c(=O)n(C(C)C(=O)OC(C)(C)C)c(=O)c12

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 1/20 0.40
▸ KDM4E B2RXH2 5/20 0.38
▸ ALDH1A1 P00352 5/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HPGD P15428 3/20 0.38
▸ HSD17B10 Q99714 1/20 0.37
▸ KCNA5 P22460 1/20 0.37
▸ EPHX2 P34913 1/20 0.36
▸ MAPKAPK2 P49137 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ DAO P14920 1/20 0.34
▸ FEN1 P39748 2/20 0.34
▸ PARP1 P09874 1/20 0.34
▸ ITGA4 P13612 1/20 0.34
▸ ITGB7 P26010 1/20 0.34
▸ SLC2A1 P11166 1/20 0.34
▸ MTNR1A P48039 1/20 0.34
▸ MTNR1B P49286 1/20 0.34
▸ TACR1 P25103 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31161114 0.84 ABCG2 (0.44) ABCG2KDM4EALDH1A1MAPTHPGD
SCHEMBL2308145 0.77 POLB (0.57) ALDH1A1HPGDPOLBDAO
SCHEMBL19410170 0.77 POLB (0.57) ALDH1A1HPGDPOLBDAO
SCHEMBL2308151 0.77 POLB (0.57) ALDH1A1HPGDPOLBDAO
SCHEMBL31161080 0.72 GPR139 (0.46) KDM4EALDH1A1HPGD
SCHEMBL2070119 0.70 ABCG2 (0.53) ABCG2KDM4EALDH1A1MAPTHPGD
SCHEMBL31160896 0.68 KMT2A (0.54) KDM4EALDH1A1HPGDPOLBFEN1
SCHEMBL31160823 0.68 KMT2A (0.54) KDM4EALDH1A1HPGDPOLBFEN1
SCHEMBL29062932 0.67 ALDH1A1 (0.44) ABCG2KDM4EALDH1A1MAPTHPGD
SCHEMBL18959798 0.65 KDM4E (0.33) KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559464-B2 Quinazolinone dione compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2026-02-24 — — US disclosed
EP-4688756-A1 QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2026-02-11 — — EP disclosed
US-20250026726-A1 QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-01-23 — — US disclosed
WO-2024206345-A1 QUINAZOLINE DIONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2024-10-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026726-A1 QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, MYLK2 ABCG2 164/4885KDM4E 2997/4885ALDH1A1 1640/4885
US-12559464-B2 Quinazolinone dione compounds and uses thereof TNNI3, TNNT2, TNNC1 ABCG2 358/4885KDM4E 2987/4885ALDH1A1 1070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback